Curevac announces financial results for the first quarter of 2023 and provides business update

Initiated phase 1/2 study in seasonal flu with multivalent, modified mrna vaccine candidates; continued execution on infectious disease development program in collaboration with gsk filed infringement counterclaim in u.s. patent litigation with pfizer/biontech; case filed under nine curevac patents; litigation timeline expected to be accelerated by successful court transfer received positive preliminary opinion of german federal patent court supporting validity of german patent challenged in nullity action by pfizer/biontech; german litigation broadened by additional curevac patent cash and cash equivalents position of €617.5 million as of march 31, 2023 tÜbingen, germany and boston, ma / accesswire / may 30, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the first quarter of 2023 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking